Literature DB >> 3279120

Induction of activated macrophages in C3H/HeJ mice by avirulent Salmonella.

R Schafer1, C A Nacy, T K Eisenstein.   

Abstract

A single injection of viable Salmonella typhimurium SL3235, an avirulent organism blocked in the aromatic pathway, induced the generation of activated peritoneal macrophages in three different C3H mouse strains, including macrophage-defective C3H/HeJ mice. Macrophages obtained from immunized mice were cytotoxic for B16 melanoma cells, P815 mastocytoma cells, and TU-5 fibrosarcoma cells and microbicidal in vitro for the obligate, intracellular, protozoan parasite Leishmania major. The capacity of live SL3235 to activate C3H/HeJ macrophages contrasts with the failure of live Bacillus Calmette-Guérin to induce activated macrophages in this mouse strain. Although viable SL3235 were capable of fully activating cells of both normal and defective mice, a dose-dependent difference was observed in the number of organisms necessary for induction of tumoricidal macrophages in C3HeB/FeJ (normal) and C3H/HeJ (defective) animals. As few as 80 viable SL3235 were capable of activating C3HeB/FeJ macrophages whereas 5 X 10(4) organisms were required to activate C3H/HeJ macrophages. Maximal macrophage activation occurred 7 to 10 days after SL3235 inoculation in C3H/HeJ and C3HeB/FeJ mice. Acetone-killed cells of SL3235 had some but not all of the activity of the living Salmonella. A single in vivo injection of the nonviable preparation resulted in the induction of tumoricidal macrophages in C3HeB/FeJ but not in C3H/HeJ mice, even when tested over a wide dosage range. Injection of acetone-killed cells of SL3235 did, however, result in a population of primed macrophages in C3H/HeJ mice, as explanted cells could be induced to express activated macrophage effector activities after additional treatment in vitro with either LPS or IFN-gamma. Thus, in vivo administration of viable SL3235 is, by itself, capable of eliciting the full series of steps required for activation of C3H/HeJ macrophages, whereas killed SL3235 only provides signals sufficient to prime these defective macrophages for further activation in vitro. AI 15613

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279120

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Interleukin-12 is critical for induction of nitric oxide-mediated immunosuppression following vaccination of mice with attenuated Salmonella typhimurium.

Authors:  M G Schwacha; T K Eisenstein
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

2.  Natural killer cells mediate protection induced by a Salmonella aroA mutant.

Authors:  R Schafer; T K Eisenstein
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

3.  Role of Toll-like receptor 4 in macrophage activation and tolerance during Salmonella enterica serovar Typhimurium infection.

Authors:  Qian Li; Bobby J Cherayil
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

4.  Immunotherapy of a plasmacytoma with attenuated salmonella.

Authors:  T K Eisenstein; B Bushnell; J J Meissler; N Dalal; R Schafer; H F Havas
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

5.  Susceptibility of lipopolysaccharide-responsive and -hyporesponsive ItyS Mice to infection with rough mutants of Salmonella typhimurium.

Authors:  I Mattsby-Baltzer; B Ahlström; L Edebo; P de Man
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

6.  In vivo blockage of nitric oxide with aminoguanidine inhibits immunosuppression induced by an attenuated strain of Salmonella typhimurium, potentiates Salmonella infection, and inhibits macrophage and polymorphonuclear leukocyte influx into the spleen.

Authors:  A S MacFarlane; M G Schwacha; T K Eisenstein
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

7.  Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells.

Authors:  A Aggarwal; S Kumar; R Jaffe; D Hone; M Gross; J Sadoff
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

Review 8.  Perspectives on Oncolytic Salmonella in Cancer Immunotherapy-A Promising Strategy.

Authors:  Ding Wang; Xiaodong Wei; Dhan V Kalvakolanu; Baofeng Guo; Ling Zhang
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.